TransMedics Group, Inc. (NASDAQ:TMDX) Shares Sold by State of New Jersey Common Pension Fund D

State of New Jersey Common Pension Fund D lowered its stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 1.1% during the third quarter, Holdings Channel reports. The firm owned 12,929 shares of the company’s stock after selling 141 shares during the period. State of New Jersey Common Pension Fund D’s holdings in TransMedics Group were worth $2,030,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of TMDX. International Assets Investment Management LLC acquired a new stake in shares of TransMedics Group in the 2nd quarter valued at about $47,000. USA Financial Formulas purchased a new stake in TransMedics Group in the third quarter valued at approximately $55,000. J.Safra Asset Management Corp boosted its holdings in shares of TransMedics Group by 649.2% in the second quarter. J.Safra Asset Management Corp now owns 442 shares of the company’s stock valued at $67,000 after acquiring an additional 383 shares during the period. Signaturefd LLC grew its position in shares of TransMedics Group by 26.6% during the second quarter. Signaturefd LLC now owns 443 shares of the company’s stock worth $67,000 after acquiring an additional 93 shares during the last quarter. Finally, Farther Finance Advisors LLC increased its holdings in shares of TransMedics Group by 187.0% in the 3rd quarter. Farther Finance Advisors LLC now owns 485 shares of the company’s stock valued at $76,000 after acquiring an additional 316 shares during the period. Hedge funds and other institutional investors own 99.67% of the company’s stock.

TransMedics Group Trading Down 8.9 %

NASDAQ:TMDX opened at $80.48 on Friday. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20. TransMedics Group, Inc. has a 1 year low of $63.85 and a 1 year high of $177.37. The stock has a market capitalization of $2.70 billion, a price-to-earnings ratio of 85.62 and a beta of 2.08. The stock has a fifty day moving average price of $125.63 and a two-hundred day moving average price of $139.09.

TransMedics Group (NASDAQ:TMDX) last issued its earnings results on Monday, October 28th. The company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.29 by ($0.17). TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The company had revenue of $108.76 million for the quarter, compared to analyst estimates of $115.00 million. During the same quarter in the previous year, the company posted ($0.12) earnings per share. The company’s quarterly revenue was up 63.7% compared to the same quarter last year. As a group, sell-side analysts anticipate that TransMedics Group, Inc. will post 1.07 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages have issued reports on TMDX. Robert W. Baird lowered their price objective on shares of TransMedics Group from $200.00 to $150.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 29th. Canaccord Genuity Group lowered their price target on TransMedics Group from $169.00 to $109.00 and set a “buy” rating on the stock in a report on Tuesday, October 29th. Stephens upped their price objective on TransMedics Group from $151.00 to $178.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. Oppenheimer lowered their target price on TransMedics Group from $200.00 to $125.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 29th. Finally, Needham & Company LLC cut their price target on TransMedics Group from $208.00 to $109.00 and set a “buy” rating for the company in a research note on Tuesday, October 29th. One research analyst has rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, TransMedics Group currently has a consensus rating of “Buy” and an average target price of $144.80.

Insider Activity at TransMedics Group

In other news, CEO Waleed H. Hassanein sold 8,625 shares of the stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $153.42, for a total value of $1,323,247.50. Following the sale, the chief executive officer now directly owns 61,643 shares in the company, valued at $9,457,269.06. This represents a 12.27 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Nicholas Corcoran sold 10,000 shares of TransMedics Group stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $176.02, for a total value of $1,760,200.00. Following the transaction, the insider now owns 21,105 shares of the company’s stock, valued at $3,714,902.10. This represents a 32.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 36,958 shares of company stock valued at $5,230,528 in the last ninety days. Corporate insiders own 7.00% of the company’s stock.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.